Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health

PROACT 3: Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.

Who May Be Eligible (Plain English)

Who May Qualify: - Current age 30-75 years - Established primary care at Mass General Brigham with at least one visit in the last 2 years Who Should NOT Join This Trial: \- Currently taking LDL cholesterol- lowering medications, including statins Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Current age 30-75 years * Established primary care at Mass General Brigham with at least one visit in the last 2 years Exclusion Criteria: \- Currently taking LDL cholesterol- lowering medications, including statins

Treatments Being Tested

BEHAVIORAL

Immediate disclosure of CAD PRS results

Participants receive their CAD PRS results as soon as they are available after genotyping.

BEHAVIORAL

Deferred Disclosure of CAD PRS results

Participants receive their CAD PRS results after completion of the 12 month follow up period.

Locations (1)

Massachusetts General Hospital
Boston, Massachusetts, United States